Skip to main content
“Knowing I have a BRAF mutation helped me get a targeted treatment for my type of cancer.”
Information Icon

Receiving a cancer diagnosis is overwhelming and comes with a lot of information to take in. Let’s look at the essential things you should know about low-grade glioma (LGG) with a BRAF V600E mutation in children.

The basics
Brain tumor icon

LGG is the most common brain tumor diagnosed in children. These tumors are typically removed through surgery and treated with chemotherapy if needed. Some children, however, may have a damaged BRAF gene—known as a mutation—that may cause the tumor to act more aggressively.


Specifically, the BRAF V600E mutation is the second most common mutation found in LGG.

Up to 1 in 5 patients with LGG have the BRAF V600E mutation
Why does the BRAF V600E mutation matter?
Mutated DNA icon

LGG tumors with a BRAF V600E mutation are stubborn and often return and continue to grow (progress), even after successful surgery. These specific tumors may also respond poorly to chemotherapy—the most frequently used treatment following surgery.


After the tumor is removed, doctors will send a sample of it to a genetic laboratory, where its DNA will be analyzed to see if it contains a BRAF mutation. A positive result means that the BRAF V600E mutation is present.

Knowing mutation status matters because it gives you access to treatment options, like TAFINLAR + MEKINIST

Important Safety Information

TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers. Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Approved Uses

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and

  • that has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.